Drug-induced osteoporosis: Beyond glucocorticoids

被引：14
作者：
Briot K. [1 ]
Roux C. [1 ]
机构：
[1] Department of Rheumatology, Cochin Hospital, 75014 Paris
来源：
Current Rheumatology Reports | 2008年 / 10卷 / 2期
关键词：
Bone Mineral Density; Osteoporosis; Bone Loss; Fracture Risk; Zoledronic Acid;
D O I：
10.1007/s11926-008-0019-4
中图分类号：
学科分类号：
摘要：
To prevent osteoporotic fractures, it is important to identify patients at high risk of fracture by assessing risk factors such as underlying diseases and drugs. Prior and current use of oral corticosteroids is strongly associated with increased fracture risk, but other medications could be involved and should be assessed as part of the optimal care of patients at risk of osteoporosis. Strong evidence points to gonadotropin-releasing hormone agonists, aromatase inhibitors, and antiepileptic drugs. Further studies are necessary to confirm the deleterious effect of other treatments on bone. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码：102 / 109
页数：7
相关论文
共 66 条
[1]  
Mittan D., Lee S., Miller E., Et al., Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs, J Clin Endocrinol Metab, 87, pp. 3656-3661, (2002)
[2]  
Daniell H.W., Tam H.W., Progressive osteoporosis during androgen deprivation therapy for prostate cancer, J Urol, 163, pp. 181-186, (2000)
[3]  
Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S., Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 152, pp. 154-164, (2005)
[4]  
Diamond T.H., Hiagno C.S., Smith M.R., Et al., Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies, Cancer, 100, pp. 892-899, (2004)
[5]  
Michaelson M.D., Kaufman D.S., Lee H., Et al., Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer, J Clin Oncol, 25, pp. 1038-1042, (2007)
[6]  
Fernandez H., Lucas C., Hedon B., Et al., One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: A randomized double blind trial, Human Reprod, 19, pp. 1465-1471, (2004)
[7]  
Howell A., Cuzick J., Baum M., Et al., the ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet, 365, pp. 60-62, (2005)
[8]  
Goss P.E., Ingle J.N., Robert N.J., Et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 349, pp. 1793-1802, (2003)
[9]  
Coombes R.C., Hall E., Gibson L.J., Et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med, 350, pp. 1081-1092, (2004)
[10]  
Coleman R.E., Banks L.M., Girgis S.I., Et al., Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women in early breast cancer participating in the Intergroup Exemestane Study (IES): A randomized controlled study, Lancet Oncol, 8, pp. 119-127, (2007)
1234567